173 related articles for article (PubMed ID: 23638183)
1. Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis.
Weide B; Faller C; Büttner P; Pflugfelder A; Leiter U; Eigentler TK; Bauer J; Forschner A; Meier F; Garbe C
PLoS One; 2013; 8(4):e63137. PubMed ID: 23638183
[TBL] [Abstract][Full Text] [Related]
2. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma.
Meier F; Will S; Ellwanger U; Schlagenhauff B; Schittek B; Rassner G; Garbe C
Br J Dermatol; 2002 Jul; 147(1):62-70. PubMed ID: 12100186
[TBL] [Abstract][Full Text] [Related]
3. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II).
Balch CM; Soong SJ; Murad TM; Ingalls AL; Maddox WA
Ann Surg; 1981 Mar; 193(3):377-88. PubMed ID: 7212800
[TBL] [Abstract][Full Text] [Related]
4. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma.
Garbe C; Hauschild A; Volkenandt M; Schadendorf D; Stolz W; Reinhold U; Kortmann RD; Kettelhack C; Frerich B; Keilholz U; Dummer R; Sebastian G; Tilgen W; Schuler G; Mackensen A; Kaufmann R
Melanoma Res; 2007 Dec; 17(6):393-9. PubMed ID: 17992123
[TBL] [Abstract][Full Text] [Related]
5. The role of sentinel lymph node biopsy in patients with local recurrence or in-transit metastasis of melanoma.
Gipponi M; Solari N; Giovinazzo D; Queirolo P; Bertoglio S; Villa G; Gualco M; Bleidl D; Cafiero F
Anticancer Res; 2014 Jun; 34(6):3197-203. PubMed ID: 24922694
[TBL] [Abstract][Full Text] [Related]
6. Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour.
Weide B; Faller C; Elsässer M; Büttner P; Pflugfelder A; Leiter U; Eigentler TK; Bauer J; Meier F; Garbe C
PLoS One; 2013; 8(6):e66953. PubMed ID: 23825594
[TBL] [Abstract][Full Text] [Related]
7. Mitotic rate in node-positive stage III melanoma: it might be as important a prognostic factor as node number.
Tas F; Erturk K
Jpn J Clin Oncol; 2021 May; 51(6):873-878. PubMed ID: 33758939
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.
Egger ME; Bhutiani N; Farmer RW; Stromberg AJ; Martin RC; Quillo AR; McMasters KM; Scoggins CR
Surgery; 2016 May; 159(5):1412-21. PubMed ID: 26775577
[TBL] [Abstract][Full Text] [Related]
9. Role of FDG-PET in the assessment of survival prognosis in melanoma.
Pleiss C; Risse JH; Biersack HJ; Bender H
Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
[TBL] [Abstract][Full Text] [Related]
10. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
[TBL] [Abstract][Full Text] [Related]
11. Treatment Outcome and Prognostic Factors for Malignant Skin Melanoma Treated with Radical Surgery.
Majewski W; Stanienda K; Wicherska K; Ulczok R; Wydmanski J
Asian Pac J Cancer Prev; 2015; 16(14):5709-14. PubMed ID: 26320440
[TBL] [Abstract][Full Text] [Related]
12. Common prognostic factors for stage III melanoma patients and for stage I and II melanoma patients with recurrence to their regional lymph nodes.
Konstadoulakis MM; Messaris E; Zografos G; Ricaniadis N; Androulakis G; Karakousis C
Melanoma Res; 2002 Aug; 12(4):357-64. PubMed ID: 12170185
[TBL] [Abstract][Full Text] [Related]
13. [Axillary recurrence after lymph node excision in malignant melanoma].
Kretschmer L; Lautenschläger C; Preusser KP; Fiedler H; Hetschko I
Langenbecks Arch Chir; 1993; 378(1):4-11. PubMed ID: 8437502
[TBL] [Abstract][Full Text] [Related]
14. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma.
Kretschmer L; Beckmann I; Thoms KM; Mitteldorf C; Bertsch HP; Neumann C
Ann Surg Oncol; 2006 Aug; 13(8):1105-12. PubMed ID: 16865591
[TBL] [Abstract][Full Text] [Related]
15. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
16. Regional non-nodal metastases of cutaneous melanoma.
Cascinelli N; Bufalino R; Marolda R; Belli F; Nava M; Galluzzo D; Santinami M; Levene A
Eur J Surg Oncol; 1986 Jun; 12(2):175-80. PubMed ID: 3709823
[TBL] [Abstract][Full Text] [Related]
17. Sentinel-node biopsy or nodal observation in melanoma.
Morton DL; Thompson JF; Cochran AJ; Mozzillo N; Elashoff R; Essner R; Nieweg OE; Roses DF; Hoekstra HJ; Karakousis CP; Reintgen DS; Coventry BJ; Glass EC; Wang HJ;
N Engl J Med; 2006 Sep; 355(13):1307-17. PubMed ID: 17005948
[TBL] [Abstract][Full Text] [Related]
18. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).
Balch CM; Soong SJ; Murad TM; Smith JW; Maddox WA; Durant JR
J Clin Oncol; 1983 Feb; 1(2):126-34. PubMed ID: 6668496
[TBL] [Abstract][Full Text] [Related]
19. Locoregional cutaneous metastasis in patients with therapeutic lymph node dissection for malignant melanoma: risk factors and prognostic impact.
Kretschmer L; Preusser KP; Neumann C
Melanoma Res; 2002 Oct; 12(5):499-504. PubMed ID: 12394192
[TBL] [Abstract][Full Text] [Related]
20. Time course and pattern of metastasis of cutaneous melanoma differ between men and women.
Mervic L
PLoS One; 2012; 7(3):e32955. PubMed ID: 22412958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
